Why Intellia Therapeutics Stock Is Rising Monday

Intellia Therapeutics Inc NTLA shares are trading higher Monday after the clinical-stage genome editing company announced data for its treatment for people living with hereditary angioedema (HAE).

What To Know: In a presentation at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023, Intellia provided updated interim results from the Phase 1 portion of the ongoing study of NTLA-2002, an in vivo CRISPR candidate being developed as a single-dose treatment for HAE.

"After a single dose of our investigational CRISPR-based therapy, patients living with hereditary angioedema experienced durable elimination of their attacks. We are thrilled to see that the earliest-dosed patients are attack free for approximately a year or longer, with NTLA-2002 demonstrating a very favorable safety profile," said John Leonard, president and CEO of Intellia.

"These remarkable attack rate reductions have been consistent, even in patients with the most severe symptoms."

A 95% mean reduction in monthly attack rate was observed across all patients after a single dose of NTLA-2002. The company said a robust level of HAE attack rate reduction was achieved at each dose level tested.

Ark Invest founder and CEO Cathie Wood was buying Intellia shares last week. She purchased shares for both the ARKK and ARKG funds on Wednesday and Thursday last week.

See Also: Chinook Therapeutics, Oracle And Other Big Stocks Moving Higher In Monday's Pre-Market Session

NTLA Price Action: Intellia shares were up 6.38% at $46 at the time of publication, according to Benzinga Pro.

Photo: Victoria_Regen from Pixabay.